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Biomedicine SelectIn conjunction with this special issue on the interactions between pathogens and their hosts, Biomedicine Select
showcases new findings about a variety of microbes some of which have a major impact on global health. Multi-
drug resistance in bacteria, recent advances in influenza research, and the use of siRNAs as potential therapeu-
tics against viruses are discussed.
Dishing the Dirt on Multidrug Resistance
Antibiotic-resistant bacteria are a serious threat to human health. A re-
cent study by D’Costa et al. reveals that multidrug-resistant microbes
are far more prevalent than previously imagined. This group examined
soil microbes for antibiotic resistance. First, they isolated spore-
forming bacteria from different environments and then selected the
actinomycetes (confirmed by sequencing 16S ribosomal DNA) for
further study. They focused on 480 actinomycetes of the genus Strep-
tomyces, because more than half of all antibiotics are derived from
this species. Hence, members of this species are likely to encode
resistance elements for the antibiotics they produce as a means of
self-protection. These 480 strains were individually tested for their
ability to grow in the presence of 21 antibiotics including natural
(such as erythromycin), semisynthetic (such as cephalexin), and syn-
thetic (ciprofloxacin) antibiotics. Strikingly, every strain was found to
be resistant to seven or eight antibiotics, even newer antibiotics. In some cases, resistance was due to the produc-
tion of inactivating enzymes that metabolized the drug. One such drug was rifampicin, a derivative of a natural
product, which is used routinely to treat mycobacterial infections (which cause diseases such as tuberculosis). Forty
percent of the bacteria resistant to rifampicin could inactivate the antibiotic. Interestingly, in a clinical setting, resis-
tance to rifampicin is caused by mutations in the bacterial target of this drug, the b subunit of RNA polymerase. Other
mechanisms of resistance include glycosylation (which inactivates telithromycin) and natural mutations in the gene
encoding the cellular target (DNA gyrase in the case of ciprofloxacin). As this study is limited to Streptomyces and
used high concentrations of antibiotics, the full spectrum of antibiotic resistance that may reside in other soil bacteria
remains unknown. Another crucial question is whether this reservoir of antibiotic resistance is a source of the genetic
elements that confer resistance to pathogens.
V.M. D’Costa et al. (2006). Science 311(5759):374–7.
Antibiotic Resistance: Bridging the Class Divide
Fluoroquinolones are widely used broad-spectrum antibiotics. Bacterial resistance to these drugs is mediated
through general mechanisms, such as the upregulation of protein efflux pumps, or specific mutations in the genes
encoding the drug targets. Robicsek et al. now demonstrate that bacteria develop resistance to fluoroquinolones by
producing an enzyme that inactivates these antibiotics. This is a curious result because fluoroquinolones are com-
pletely synthetic antibiotics, not derived from natural compounds made by microbes in the environment. Even more
intriguing is the fact that the enzyme that modifies the fluoroquinolone ciprofloxacin—aminoglycoside acetyltrans-
ferase—also modifies a completely different class of antibiotics called the aminoglycosides. The investigators found
that the aac(60)-Ib-cr gene variant encodes the aminoglycoside acetyltransferase, which inactivates ciprofloxacin.
This gene variant, located on a plasmid, renders bacteria resistant to low concentrations of ciprofloxacin. When
this gene is combined with another plasmid-encoded gene, qnrA, the bacteria become resistant to clinically relevant
concentrations of ciprofloxacin. Importantly, plasmids containing these two genes are found in clinical isolates of
pathogenic Escherichia coli. Two specific mutations in aac(60)-Ib-cr are responsible for bacterial resistance to cipro-
floxacin; these mutations do not interfere with the acetylation of aminoglycoside antibiotics. Acetylation of
ciprofloxacin, which inactivates this antibiotic, occurs on a specific nitrogen atom that is not present in all fluoroqui-
nolones. Thus, bacteria harboring plasmids containing aac(60)-Ib-cr are not resistant to all fluoroquinolones.
However, bacterial resistance to multiple classes of antibiotics provides a strong positive selection pressure and
is becoming more common. The next step is to determine the prevalence of the aac(60)-Ib-cr and qnrA genes in dif-
ferent bacterial populations and to discern whether there are other examples of inactivation strategies that span
different classes of antibiotics.
A. Robicsek et al. (2006). Nature Medicine, 12(1):83–8. Published online 20 December 2005.10.1038/nm1347.
Influenza A Virus Genomes in the Spotlight
Obenauer et al. have at their disposal the St. Jude Influenza Repository from which they sequenced 336 strains of
avian influenza virus (AIV) from many different bird species and from different regions of the world. Included in this
number are examples from all known hemagglutinin (HA) and neuraminidase (NA) serotypes. These two viral surface
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glycoproteins are important targets of the host immune system and are the principal components that undergo re-
assortment between different influenza viruses to create new viral strains. In this study, Obenauer et al. report the
analysis of 2196 new AIV gene sequences and 169 complete AIV genomes. This information allowed the authors
to further classify the different influenza virus strains. The majority of avian virus genomes exhibit variability in the
genes encoding HA, NA, and the nonstructural proteins NS1 and NS2. As HA and NA are targeted by the host im-
mune system, it is not surprising that these components exhibit pronounced variability. The nonstructural proteins
encoded by the NS gene are synthesized in AIV-infected cells but are not packaged into virions. The NS1 protein
inhibits expression of host antiviral genes that encode interferons, the transcription factor NF-kB, and the protein
kinase PKR. By analyzing the NS gene in the sequenced AIV genomes, the authors discovered a previously unrec-
ognized PDZ domain binding motif (PL) in the carboxyl terminus of all avian NS1 proteins. PDZ domains provide
a platform for the assembly of signaling molecules. The authors discovered subtle differences in the PL domains
of NS1 from avian and human influenza viruses. Synthetic peptides and full-length avian and human NS1 proteins
were tested for binding to PDZ domains. Importantly, PL motifs from avian but not human strains of influenza virus
bind to the PDZ domains of a variety of human proteins. This may contribute to AIV pathogenicity in humans as the
avian NS1 protein may block different signaling pathways in infected human cells. This study provides a wealth of
information that can be tapped by researchers analyzing avian influenza viruses that may have pandemic potential.
J.C. Obenauer et al. (2006). Science. Published online 26 January 2006, 10.1126/science.1121586.
Getting to the Heart of the Virion
Understanding the basic organization of the influenza A virus may provide
clues to the best strategies to combat this pathogen. In their new study,
Noda et al. longitudinally and transversely sectioned influenza A virions bud-
ding from MDCK-cultured cells 10 hr postinfection and analyzed these
sections by electron microscopy. The authors show that Influenza A virions
appear to include a set of eight rod-like structures (see figure). This organi-
zation was observed in all tested strains: both spherical and filamentous (as
seen in newly isolated strains). Using immunoelectron microscopy, the in-
vestigators showed that the particles correspond to ribonucleoprotein
complexes (RNPs). These results address a controversy in the field of influ-
enza research, namely whether the RNPs are packaged randomly or in an
ordered fashion. Combined with previous studies indicating that the RNPs
have segment-specific packaging signals, an organized packaging model
seems likely. These signals must be fairly well-conserved, and perhaps mol-
ecules that interfere with the packaging of RNPs may represent a new
therapeutic opportunity.
T. Noda et al. (2006). Nature, 439(7075):490–2.
siRNAs: A Promising Alternative to Vaccination?
Palliser et al. use siRNAs to prevent transmission of lethal herpes simplex virus 2 (HSV-2) in mice. First, they estab-
lished that siRNAs were taken up by the vaginal epithelial cells of mice when they administered fluorescently labeled
siRNAs mixed with a transfection reagent into the mouse vagina. These siRNAs silenced gene expression for over
a week throughout the genital tissue. Next, they showed that siRNAs designed to target the degradation of three
essential HSV-2 mRNAs reduced viral replication and virion production in fibroblasts cultured in vitro. One particular
siRNA called U29.2—which is complementary to the sequence of a viral DNA binding protein—was the most effec-
tive at suppressing viral replication in cultured cells. The authors then tested whether these siRNAs could protect
mice from HSV-2 infection. Seventy-five percent of animals pretreated with UL29.2 and then infected with HSV-2
survived, compared to only 25% of control animals. When pretreated with another siRNA, UL27.2 (which targets
degradation of the HSV-2 viral envelope glycoprotein), 60% of mice infected with HSV-2 survived. Shedding
of HSV-2 from the mouse vaginal epithelium was measured 6 days after infection. All infected control mice shed
virus on day 6, but the virus could not be detected in 70% of UL29.2 siRNA-treated mice or in 50% of UL27.2
siRNA-treated animals. The cervico-vaginal mucosa, which is damaged during HSV-2 infection, appeared healthy
in the siRNA-treated mice. When animals were treated with siRNAs 3 or 6 hr after infection with HSV-2, only a com-
bination of UL29.2 and UL27.2 succeeded in protecting them (5 of 6 mice survived). Palliser and colleagues provide
a compelling study that demonstrates the potential use of siRNAs to treat or prevent sexually transmitted viral infec-
tions. Importantly, treatment of mice with siRNAs after infection with HSV-2 also was effective. Although many
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aspects of using siRNAs to treat viral infections—such as how long protection lasts, methods for easy administration
of siRNAs and cost—need to be worked out, this study is an important step forward in our strategies to combat viral
pathogens.
D. Palliser et al. (2006). Nature. 439(7072):89–94. Published online 23 November 2005, 10.1038/nature04263.
Molecular Mimicry Strikes Again
Valderrama et al. compared the wild-type vaccinia virus (Western Re-
serve; WR) to the attenuated modified vaccinia Ankara (MVA) strain to
understand why the WR strain causes infected cells to migrate and to
extend projections, whereas the MVA strain does not (see figure). The
authors were able to attribute this difference to the F11L gene as
expression of this gene in the MVA virus induced migration and
morphological changes in infected cells. Expression of this gene in un-
infected cells caused a decrease in actin stress fibers. This phenotype
is similar to that observed after expression of a dominant-negative
version of the small GTPase RhoA. Interestingly, F11L blocked stress
fiber formation induced by a constitutively active version of RhoA,
indicating that F11L might inhibit signal transduction pathways medi-
ated by RhoA. RhoA and F11L interacted both in vitro and in infected
cultured cells, and the interaction is mediated by the C terminus of
F11L. On closer inspection, the authors noticed some homology be-
tween amino acid residues in this C-terminal region of F11L with a
domain in the Rho-associated kinase ROCK. Furthermore, these res-
idues in ROCK mediate the interaction with RhoA. Mutations in this
region of F11L affected the interaction with RhoA and did not stimulate
the production of cell projections when expressed in MVA-infected
cells. The authors go on to show that F11L interfered with the ability
of RhoA to interact with ROCK as well as with mDia, another regulator
of actin organization. F11L is highly conserved among the orthopoxvi-
ruses and is essential for the production of virus particles. This
key protein in important for viral assembly as well as cell motility
and may be a good target for developing drugs to limit the spread of
orthopoxviruses.
F. Valderrama et al. (2006). Science 311(5759):377–81.
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